SIADH Diagnosis and Management

Diagnostic Criteria

The American College of Physicians recommends that a patient with hypotonic hyponatremia, inappropriately concentrated urine, and low plasma osmolality is diagnosed with SIADH, which is the most common paraneoplastic endocrine phenomenon associated with small cell lung cancer, with a plasma osmolality of 260 mOsm/kg (normal 275-290 mOsm/kg) 1
The European Society of Medical Oncology states that inappropriately concentrated urine with osmolality of 1200 mOsm/kg when it should be maximally dilute (<100 mOsm/kg) in the setting of low plasma osmolality is a key diagnostic criterion for SIADH 1, 2
The presence of small cell lung carcinoma is a clinical context that is commonly associated with SIADH as a paraneoplastic syndrome, with SIADH occurring in approximately 10-45% of small cell lung cancer cases 1, 3

The National Comprehensive Cancer Network recommends fluid restriction to <1 L/day as first-line treatment for asymptomatic or mild SIADH in patients with small cell lung cancer 1, 3
The American Society of Clinical Oncology suggests that discontinuing implicated medications, such as platinum-based chemotherapy, vinca alkaloids, opioids, and NSAIDs, is necessary for the treatment of SIADH in SCLC patients 3
For severe symptomatic hyponatremia (<120 mEq/L with neurological symptoms), the administration of 3% hypertonic saline with a target correction of 6 mEq/L over 6 hours or until symptoms resolve is recommended, with a maximum correction of 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 1, 2